In August 2022, these guidelines were reviewed by an expert work group convened by ASH.
Review included limited searches for new evidence and discussion of the search results …

Background Thrombolytic therapy is usually reserved for patients with clinically serious or
massive pulmonary embolism (PE). Evidence suggests that thrombolytic agents may …

Background This is the 2nd update to the 9th edition of these guidelines. We provide
recommendations on 17 PICO (Population, Intervention, Comparator, Outcome) questions …

Background Thrombolytic therapy is usually reserved for people with clinically serious or
massive pulmonary embolism (PE). Evidence suggests that thrombolytic agents may …

Background We aimed to review the efficacy and safety of recanalisation procedures for the
treatment of PE. Methods We searched PubMed, the Cochrane Library, EMBASE, EBSCO …

Thrombolytic therapy might reduce venous thromboembolism–related mortality and
morbidity, but it could also increase the risk of major bleeding. We systematically reviewed …

Background Acute pulmonary embolism (PE) with preserved hemodynamics but right
ventricular dysfunction, classified as submassive PE, carries a high risk of mortality. We …

Background Acute pulmonary embolism (PE) is a serious condition that needs quick and
effective treatment. Anticoagulation therapy is the usual care for most PE patients but may …

Objective: The objective of this study is to compare the efficacy and safety of thrombolysis
plus anticoagulant therapy vs. anticoagulant therapy alone in acute submassive pulmonary …

Background: Thrombolytic agents and anticoagulants are the two classes of medication
used in the treatment of acute pulmonary embolism (PE). There is continuous renewal and …